1190363-03-1

Basic information

• Product Name: BMS-846372
• Synonyms: BMS-846372
• CAS NO: 1190363-03-1
• Molecular Weight: 519.551
• Mol File: 1190363-03-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: BMS-846372(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-846372(1190363-03-1)
• EPA Substance Registry System: BMS-846372(1190363-03-1)

Safety Data

• Hazardous Substances Data: 1190363-03-1(Hazardous Substances Data)

Upstream product

• 1190363-49-5 (6R,9R)-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol 
• 1190363-91-7 4-nitrophenyl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-piperidine-1-carboxylate 
• 1397525-83-5 (5S,6S,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-ol hydrochloride 
• 1190363-51-9 (5S,6S,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-yl methanesulfonate 
• 1190363-52-0 (6R,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine 
• 1190363-44-0 (R)-9-hydroxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one hydrochloride 
• 39713-40-1 7,8-dihydro-5H-cyclohepta[b]pyridine-5,9(6H)-dione 
• 1190363-46-2 (6S,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-5-one 
• 1190363-45-1 (R)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one 
• 39713-36-5 dimethyl 5,9-dihydroxy-7H-cyclohepta[b]pyridine-6,8-dicarboxylate 
• 1354640-52-0 (9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-5-one 
• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 128071-75-0 2-bromopyridine-3-carboxaldehyde 
• 74912-33-7 nona-1,8-dien-5-one 

Relevant articles and documents

Efficient and scalable enantioselective synthesis of a CGRP antagonist

An enantioselective synthesis of the CGRP antagonist BMS-846372, amenable to large scale preparation, is presented. This new synthesis showcases a chemo- and enantioselective reduction of a cyclohepta[b]pyridine-5,9-dione as well as a Pd-catalyzed alpha-arylation reaction to form the key carbon-carbon bond and set the absolute and relative stereochemistry.

CGRP Receptor Antagonists

The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).